



## **Cardiovascular Disease** Scorecards - Australia

#### **AUSTRALIA – JUNE 2022**

### Status of Cardiovascular Disease (CVD) and Non-communicable diseases (NCD)

### **Country Demographics**

**World Bank** Classification High income



**Life expectancy** at birth (in years):

**MALE** 81.2



**FEMALE** 

85.3

**†††86.2%** 

of population living in **urban** areas

of age) (% of deaths):

Total mortality due to CVD (% of deaths):

male: 28.63% female: 31.93%



female: 33.2%


Percentage of adult population with raised total **cholesterol** (≥5.0 mmol/L)

Global data: 38.9%

Percentage of adult population (age-stand-

ardized) with raised blood pressure (SBP ≥140 or DBP ≥90) Global data: 24.1% (male) **20.1%** (female)

**Premature mortality** due to CVD (death during 30-70 years





Proportion of premature CVD mortality attributable to tobacco (%)

Percentage of adults (age-standardized estimate) who are insufficiently active (less than **150 minutes** of moderate intensity physical activity per week, or less than 75 minutes of vigorous-intensity physical activity per week):

male: 27%





**FEMALE MALE** 

female: 33.6%





Prevalence of diabetes in




Percentage of adolescents (ages 11-17) who are insufficiently active (less than **60 minutes** of moderate- to vigorous intensity physical activity daily):

> <sup>1</sup>male: 86.8% female: 91.4%

Percentage of adults who are overweight (body mass index (BMI) of 25 kg/m2 or higher):

male: 70.9% female: **58.1%** 







# Cardiovascular Disease Scorecards – Australia



KEY:

No data



Not in place



In process/ partially implemented



In place



			. •
Essential	<b>Medicines</b>	and Inter	ventions

Following essential medicines generally available in primary care facilities in the public health sector:

ACE inhibitors:	Metformin:
Aspirin:	Insulin:
Beta blockers:	Warfarin:
Statins:	Clopidrogrel:

### **Clinical Practice and Guidelines**

Locally-relevant (national or subnational level):

Clinical tool to assess CVD risk:
CVD prevention (within the last 5 years):
Treatment of tobacco dependence:
Detection and management of Atrial Fibrillation:

### **Cardiovascular Disease Governance**

A National strategy or plan that addresses:
CVDs and their risk factors specifically:
A national tobacco control plan:
A national multisectoral coordination mechanism for tobacco control:
A national surveillance system that includes
CVDs and their risk factors:
Policies that ensure screening of individuals
at high risk of CVDs:



### Stakeholder action

NGO advocacy for CVD policies and programmes:	
Active involvement of patients' organizations in advocacy for CVD prevention and management:	
Involvement of civil society in the development and implementation of a national CVD prevention and control plan:	
Involvement of civil society in the national multisectoral coordination mechanism for NCDs/CVDs:	
Specific activities by cardiology professional associations aimed at 25% reduction in premature CVD mortality by 2025:	
Hypertension screening by businesses at workplaces:	

For more information, please email info@worldheart.org